First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
But the Day One deal is still 29% below where the shares stood at the start of this year.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
The response rate jumps to 30% with higher doses of IMA402.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
After more discontinuations, a new deal brings in fresh blood.
The CD70-targeting CTX131 heads for the scrapheap.